

Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

CD34 APC

RRID:AB_2686894

Type: Antibody

Proper Citation

BD Biosciences Cat# 345804, RRID:AB_2686894

Antibody Information

URL: http://antibodyregistry.org/AB_2686894

Proper Citation: BD Biosciences Cat# 345804, RRID:AB_2686894

Target Antigen: CD34

Host Organism: mouse

Clonality: monoclonal

Antibody Name: CD34 APC

Description: This monoclonal targets CD34

Target Organism: human

Clone ID: 8G12

Antibody ID: AB_2686894

Vendor: BD Biosciences

Catalog Number: 345804

Record Creation Time: 20231110T034046+0000

Record Last Update: 20260829T013149+0000

Ratings and Alerts

No rating or validation information has been found for CD34 APC.

No alerts have been found for CD34 APC.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Haladik B, et al. (2025) Image-based drug screening combined with molecular profiling identifies signatures and drivers of therapy resistance in pediatric AML. Cell reports. Medicine, 6(9), 102304.

Kaiser FMP, et al. (2023) IL-7 receptor signaling drives human B-cell progenitor differentiation and expansion. Blood, 142(13), 1113.

Brabson JP, et al. (2023) Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia. Cell reports, 42(1), 112027.

Cieřla M, et al. (2023) m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis. Molecular cell, 83(7), 1165.

Zhu H, et al. (2020) Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity. Cell stem cell, 27(2), 224.

Li Y, et al. (2018) Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell stem cell, 23(2), 181.